2019 novel coronavirus disease (covid-19) · 2020-06-12 · what we’ll discuss this morning •...

40
George W. Rutherford, M.D., A.M. Salvatore Pablo Lucia Professor of Epidemiology, Preventive Medicine, Pediatrics and History Head, Division of Infectious Disease and Global Epidemiology Department of Epidemiology and Biostatistics School of Medicine Institute for Global Health Sciences University of California, San Francisco 17 June 2020 2019 novel coronavirus disease (COVID-19) for Advances in Internal Medicine 2020

Upload: others

Post on 15-Aug-2020

2 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: 2019 novel coronavirus disease (COVID-19) · 2020-06-12 · What we’ll discuss this morning • Human coronaviruses in general, SARS, MERS and the novel coronavirus, SARS-CoV-2

George W. Rutherford, M.D., A.M.Salvatore Pablo Lucia Professor of Epidemiology, Preventive Medicine, Pediatrics and History

Head, Division of Infectious Disease and Global EpidemiologyDepartment of Epidemiology and Biostatistics

School of MedicineInstitute for Global Health Sciences

University of California, San Francisco17 June 2020

2019 novel coronavirus disease (COVID-19)for Advances in Internal Medicine 2020

Page 2: 2019 novel coronavirus disease (COVID-19) · 2020-06-12 · What we’ll discuss this morning • Human coronaviruses in general, SARS, MERS and the novel coronavirus, SARS-CoV-2

What we’ll discuss this morning

• Human coronaviruses in general, SARS, MERS and the novel coronavirus, SARS-CoV-2

• The emergence of SARS-CoV-2 and its associated disease (COVID-19) in Wuhan, China

• Current epidemiology• Some historical and current

perspectives on face coverings

Page 3: 2019 novel coronavirus disease (COVID-19) · 2020-06-12 · What we’ll discuss this morning • Human coronaviruses in general, SARS, MERS and the novel coronavirus, SARS-CoV-2

Human coronaviruses, severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS) and the novel 2019 coronavirus

Page 4: 2019 novel coronavirus disease (COVID-19) · 2020-06-12 · What we’ll discuss this morning • Human coronaviruses in general, SARS, MERS and the novel coronavirus, SARS-CoV-2

Coronaviruses

• Before SARS (2002), coronaviruses were considered relatively inconsequential pathogens that caused common colds

• Four human coronaviruses are endemic globally and cause 10-30% of upper respiratory tract infections in adults (alpha coronaviruses HCoV 2229E, NL 63, OC 43, HKU 1)

• Widely distributed in mammals and birds• Since 2002 we’ve recognized two highly pathogenic strains that

causes severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS)

Page 5: 2019 novel coronavirus disease (COVID-19) · 2020-06-12 · What we’ll discuss this morning • Human coronaviruses in general, SARS, MERS and the novel coronavirus, SARS-CoV-2

SARS and MERS• As opposed to the human coronaviruses that are associated with

upper respiratory tract infections, SARS and MERS are caused by beta coronaviruses

• Primarily cause lower respiratory tract infection (pneumonia)• Relatively high case fatality rates

SARS MERS

Cases 8098 2494

Deaths 774 858

Case fatality rate 9.5% 34.4%

Controlled Yes after reached pandemic No, continued transmission

Other features 58% from nosocomial transmission 70% of cases from nosocomial transmission

Page 6: 2019 novel coronavirus disease (COVID-19) · 2020-06-12 · What we’ll discuss this morning • Human coronaviruses in general, SARS, MERS and the novel coronavirus, SARS-CoV-2

SARS and MERS• Both closely related to bat

strains of coronavirus• Transmitted through other

secondarily infected species• SARS Himalayan palm civets • MERS dromedaries

• SARS originally associated with wet market in Guangzhou

• 26 countries• $10-$30B economic damage

SARS

MERS

SARS-CoV-2

From: Lu R, Li J, N P, et al. Genomic characterisation of and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020 Jan 29 [Epub ahead of print].

Page 7: 2019 novel coronavirus disease (COVID-19) · 2020-06-12 · What we’ll discuss this morning • Human coronaviruses in general, SARS, MERS and the novel coronavirus, SARS-CoV-2

SARS-CoV-2• Spike (S) protein binds to angiotensin-

converting enzyme 2 (ACE2) on the membranes of lung alveolar cells, upper airway epithelial cells and glandular cells of the GI tract

Binding site

Page 8: 2019 novel coronavirus disease (COVID-19) · 2020-06-12 · What we’ll discuss this morning • Human coronaviruses in general, SARS, MERS and the novel coronavirus, SARS-CoV-2

Emergence of SARS-CoV-2 and its associated disease (COVID-19 in Wuhan, China

Page 9: 2019 novel coronavirus disease (COVID-19) · 2020-06-12 · What we’ll discuss this morning • Human coronaviruses in general, SARS, MERS and the novel coronavirus, SARS-CoV-2

Emergence of the 2019 novel coronavirus (SARS-CoV-2)• First case (COVID-19) hospitalized 17 December 2019• Cluster reported on 30 December• Huanan Wholesale Seafood Market closed 1 January• COVID-19 isolated 7 January• COVID-19 sequenced 10 January• Rapid diagnostic tests developed and distributed• Cordon sanitaire implemented in Wuhan and surrounding cities on 23 January –

59 million people quarantined• WHO declared Public Health Emergency of International Concern 30 January• Outbreak grew from a handful of cases exposed at Huanan wholesale seafood

market to more than 2.5 million cases and 180 000 deaths in less than 4 months with ongoing person-to-person transmission primarily via respiratory droplet

Page 10: 2019 novel coronavirus disease (COVID-19) · 2020-06-12 · What we’ll discuss this morning • Human coronaviruses in general, SARS, MERS and the novel coronavirus, SARS-CoV-2
Page 11: 2019 novel coronavirus disease (COVID-19) · 2020-06-12 · What we’ll discuss this morning • Human coronaviruses in general, SARS, MERS and the novel coronavirus, SARS-CoV-2

Epizoology of COVID-19

• Genetic sequence close to bat strains of coronavirus

• Suggestion of a secondary host, which acquired COVID-19 from bats and transmitted it to humans at Huanan Wholesale Seafood Market

• Possible candidate is the pangolin, a mammal whose scales used in traditional medicine

• Most illegally trafficked animal in the world

Page 12: 2019 novel coronavirus disease (COVID-19) · 2020-06-12 · What we’ll discuss this morning • Human coronaviruses in general, SARS, MERS and the novel coronavirus, SARS-CoV-2

COVID-19 cases by date of onset and date of report, China 2018-2019*

*Through 1 March 2020

Page 13: 2019 novel coronavirus disease (COVID-19) · 2020-06-12 · What we’ll discuss this morning • Human coronaviruses in general, SARS, MERS and the novel coronavirus, SARS-CoV-2

Transmission dynamics of COVID-19, China• The majority of cases arose from close contacts of symptomatic cases

• 1.5% of close contacts in China developed COVID-19

• Transmission was driven by family clusters (75-85% of infected contacts)• Secondary household attack rates with ~10% early in the outbreak and fell

to 3% with faster isolation• Transmission in closed settings happened but was not a major driver in

China (health facilities, nursing homes, prisons)• Transmission in schools was not been observed in China; this may simply

be because of the closure of schools during most of the outbreak• Did China underreport deaths, especially in the waning days of the

epidemic?

Page 14: 2019 novel coronavirus disease (COVID-19) · 2020-06-12 · What we’ll discuss this morning • Human coronaviruses in general, SARS, MERS and the novel coronavirus, SARS-CoV-2

Modeling unreported cases, Wuhan

• Wang and colleagues modeled the epidemiology of 25,961 laboratory-confirmed cases in Wuhan through 18 February

• Examined four periods: 1-10 January, 11-22 January, 23 January-1 February (first week of lockdown) and 2-18 February

• “Unascertained” = undiagnosed because they were asymptomatic or mildly symptomatic

• Major findings: Re decreased from 3.86 to 0.32 over the four periods

• 59% of cases were unascertained

Wang C, Liu L, Hao X, et al. Evolving epidemiology and impact of non-pharmaceutical interventions on the outbreak of coronavirus disease 2019 in Wuhan, China. medRxiv 2020 Mar 3 [Epub ahead of print].

Page 15: 2019 novel coronavirus disease (COVID-19) · 2020-06-12 · What we’ll discuss this morning • Human coronaviruses in general, SARS, MERS and the novel coronavirus, SARS-CoV-2

Prevalence of SARS-CoV-2 asymptomatic infection

Oran DP, Topol EJ, Prevalence of asymptomatic SARS-CoV-2 infection. A narrative review. Ann Intern Med 2020 [Epub ahead of print].

Page 16: 2019 novel coronavirus disease (COVID-19) · 2020-06-12 · What we’ll discuss this morning • Human coronaviruses in general, SARS, MERS and the novel coronavirus, SARS-CoV-2

Is health-care resource availability associated with COVID-19 mortality?

Ji Y, Ma Z, Peppelenbosch MP, Pan Q. Potential association between COVID-19 mortality and health-care resource availability [Letter]. Lancet Global Health 2020 Feb 25 [E pub ahead of print].

Page 17: 2019 novel coronavirus disease (COVID-19) · 2020-06-12 · What we’ll discuss this morning • Human coronaviruses in general, SARS, MERS and the novel coronavirus, SARS-CoV-2

Worobey M, PikarJ, Larsen B, et al. The emergence of SARS-Co-V-2 in Europe and the US. bioRxiv 2020 May 23.

Page 18: 2019 novel coronavirus disease (COVID-19) · 2020-06-12 · What we’ll discuss this morning • Human coronaviruses in general, SARS, MERS and the novel coronavirus, SARS-CoV-2
Page 19: 2019 novel coronavirus disease (COVID-19) · 2020-06-12 · What we’ll discuss this morning • Human coronaviruses in general, SARS, MERS and the novel coronavirus, SARS-CoV-2
Page 20: 2019 novel coronavirus disease (COVID-19) · 2020-06-12 · What we’ll discuss this morning • Human coronaviruses in general, SARS, MERS and the novel coronavirus, SARS-CoV-2

COVID-19 cases and deaths, United States, 2020

1,956,499 cases 110,932 deaths

Page 21: 2019 novel coronavirus disease (COVID-19) · 2020-06-12 · What we’ll discuss this morning • Human coronaviruses in general, SARS, MERS and the novel coronavirus, SARS-CoV-2
Page 22: 2019 novel coronavirus disease (COVID-19) · 2020-06-12 · What we’ll discuss this morning • Human coronaviruses in general, SARS, MERS and the novel coronavirus, SARS-CoV-2
Page 23: 2019 novel coronavirus disease (COVID-19) · 2020-06-12 · What we’ll discuss this morning • Human coronaviruses in general, SARS, MERS and the novel coronavirus, SARS-CoV-2

COVID-19 cases by county, California, 2020

Page 24: 2019 novel coronavirus disease (COVID-19) · 2020-06-12 · What we’ll discuss this morning • Human coronaviruses in general, SARS, MERS and the novel coronavirus, SARS-CoV-2

COVID-19 cases by week.San Francisco County

0 0 0 0 0 832

68

232 228

304285

251

194

341

148

276

191 189

0

50

100

150

200

250

300

350

400

27-Jan 3-Feb 10-Feb 17-Feb 24-Feb 2-Mar 9-Mar 16-Mar 23-Mar 30-Mar 6-Apr 13-Apr 20-Apr 27-Apr 4-May 11-May 18-May 25-May 1-Jun

Shelter in place

Page 25: 2019 novel coronavirus disease (COVID-19) · 2020-06-12 · What we’ll discuss this morning • Human coronaviruses in general, SARS, MERS and the novel coronavirus, SARS-CoV-2

2 0 0 0 650

184

490

1069

1622

12701226

1116

9781080

906

1397 1373 1389

0

200

400

600

800

1000

1200

1400

1600

1800

27-Jan 3-Feb 10-Feb 17-Feb 24-Feb 2-Mar 9-Mar 16-Mar 23-Mar 30-Mar 6-Apr 13-Apr 20-Apr 27-Apr 4-May 11-May 18-May 25-May 1-Jun

COVID-19 cases by week.Bay Area Counties

Shelter in place

Page 26: 2019 novel coronavirus disease (COVID-19) · 2020-06-12 · What we’ll discuss this morning • Human coronaviruses in general, SARS, MERS and the novel coronavirus, SARS-CoV-2

Infectious disease deaths, United States, 1900-1996

Armstrong GL, Conn LA, Pinner RW. Trends in infectious disease mortality in the United States during the 20th century. JAMA 1999; 281:61-66.

Page 27: 2019 novel coronavirus disease (COVID-19) · 2020-06-12 · What we’ll discuss this morning • Human coronaviruses in general, SARS, MERS and the novel coronavirus, SARS-CoV-2

Two strategic goals

• Limit new cases by decreasing Re, the effective reproductive number• Flatten and prolong the outbreak to (1) assure adequacy of health

care resources and (2) buy time for antivirals and eventually vaccine

Page 28: 2019 novel coronavirus disease (COVID-19) · 2020-06-12 · What we’ll discuss this morning • Human coronaviruses in general, SARS, MERS and the novel coronavirus, SARS-CoV-2

Effective reproductive number (Re)

Courtesy of Dr. Wan Yang, Columbia University

Page 29: 2019 novel coronavirus disease (COVID-19) · 2020-06-12 · What we’ll discuss this morning • Human coronaviruses in general, SARS, MERS and the novel coronavirus, SARS-CoV-2

Effects of pandemic mitigation on health care needs

Page 30: 2019 novel coronavirus disease (COVID-19) · 2020-06-12 · What we’ll discuss this morning • Human coronaviruses in general, SARS, MERS and the novel coronavirus, SARS-CoV-2

Empirical evidence that social distancing works• Two adjacent Italian provinces in

Lombardy region• One (Lodi) began shelter-in-place on

26 February• Other (Bergamo) began shelter-in-

place on 9 March • Empirical evidence that shelter in

place orders can blunt transmission and new disease

https://www.ilsole24ore.com/art/coronavirus-dati-lodi-dimostrano-misure-lockdown-rallentano-contagio-ADo675B

COVID-19 cases by day, Lodi and Bergamo provinces, Italy, February-April, 2020

0

100

200

300

400

500

600

700

800

26-F

eb5-

Mar

13-M

ar21

-Mar

29-M

ar6-

Apr

14-A

pr22

-Apr

30-A

pr8-

May

16-M

ay24

-May

1-Ju

n

Lodi

INTERVENTION

26-F

eb5-

Mar

13-M

ar21

-Mar

29-M

ar6-

Apr

14-A

pr22

-Apr

30-A

pr8-

May

16-M

ay24

-May

1-Ju

n

Bergamo

INTERVENTION

Recalculation of prior weeks 419 cases

Page 31: 2019 novel coronavirus disease (COVID-19) · 2020-06-12 · What we’ll discuss this morning • Human coronaviruses in general, SARS, MERS and the novel coronavirus, SARS-CoV-2

Is social distancing working in San Francisco?COVID-19 cases by day, San Francisco and Los Angeles, March-June, 2020

San Francisco

0

200

400

600

800

1000

1200

1400

1600

Los Angeles

0

500

1000

1500

2000

2500

Shelter in place Shelter in place

First COVID-19 deathFirst COVID-19 death

Page 32: 2019 novel coronavirus disease (COVID-19) · 2020-06-12 · What we’ll discuss this morning • Human coronaviruses in general, SARS, MERS and the novel coronavirus, SARS-CoV-2
Page 33: 2019 novel coronavirus disease (COVID-19) · 2020-06-12 · What we’ll discuss this morning • Human coronaviruses in general, SARS, MERS and the novel coronavirus, SARS-CoV-2

San Francisco and the 1918-19 influenza epidemic

Page 34: 2019 novel coronavirus disease (COVID-19) · 2020-06-12 · What we’ll discuss this morning • Human coronaviruses in general, SARS, MERS and the novel coronavirus, SARS-CoV-2

Comparative excess mortality per 100 000 by days since 7 September 1918, United States

Bootsma MCJ, Ferguson MN. The effect of public health measures on the 1918 influenza pandemic in U.S. cities. Proc Natl Acad Sci 2007; 104:7488-93.

Predicted excess mortality

Actual excess mortality

PH closures, masks

Page 35: 2019 novel coronavirus disease (COVID-19) · 2020-06-12 · What we’ll discuss this morning • Human coronaviruses in general, SARS, MERS and the novel coronavirus, SARS-CoV-2

Kimberly A. Prather et al. Science 2020;science.abc6197

Page 36: 2019 novel coronavirus disease (COVID-19) · 2020-06-12 · What we’ll discuss this morning • Human coronaviruses in general, SARS, MERS and the novel coronavirus, SARS-CoV-2

• Masks as droplet source control (rather than PPE)• Effectiveness of blocking droplets during speech

when droplets are at low pressure and have not desiccated to smaller sizes (<1µm)

• Surgical masks block coronaviruses of all sizes (Leung, Nat Med 2020)

• Cotton masks block 96% of viral load within 8 inches of mask of COVID-19 patient (Base, Ann Intern Med 2020)

• 0 of 25 passengers and flight attendants near a COVID-19 patient with a mask developed infection on flight from China to Toronto (Schwartz, CMAJ 2020)

• Compliance increased in Mexico City in 2009 when masks became mandatory rather than voluntary (Condon, Health Pol 2010)

Page 37: 2019 novel coronavirus disease (COVID-19) · 2020-06-12 · What we’ll discuss this morning • Human coronaviruses in general, SARS, MERS and the novel coronavirus, SARS-CoV-2

Modeling benefit of universal masking post-shelter-in-place

Kai D, Goldstein G-P, Morgunov A, Nangalia V, Rotkirch A. Universal masking is urgent in the COIVD-19 pandemic: SEIR and agent based models, empirical validation, policy recommendations. arXiv 2020 Apr 22; 2004.13553v1.

Page 38: 2019 novel coronavirus disease (COVID-19) · 2020-06-12 · What we’ll discuss this morning • Human coronaviruses in general, SARS, MERS and the novel coronavirus, SARS-CoV-2

Crowd events and potential for SARS-CoV-2 transmission, Texas and Arizona, Memorial Day, 2020

Page 39: 2019 novel coronavirus disease (COVID-19) · 2020-06-12 · What we’ll discuss this morning • Human coronaviruses in general, SARS, MERS and the novel coronavirus, SARS-CoV-2

Will protests increase transmission of SARS-CoV-2?

Page 40: 2019 novel coronavirus disease (COVID-19) · 2020-06-12 · What we’ll discuss this morning • Human coronaviruses in general, SARS, MERS and the novel coronavirus, SARS-CoV-2